B
Blue Earth Therapeutics
Targeted radiotherapeutics for prostate cancer treatment
About Blue Earth Therapeutics
Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company founded in 2021 in Oxford, UK, as a subsidiary of the Bracco Group. The company was established to advance the development of next-generation targeted radiotherapeutics for cancer treatment. David Gauden, who co-founded the sister company Blue Earth Diagnostics, led the spin-out of Blue Earth Therapeutics and serves as its CEO. His background includes over 25 years in the radiopharmaceuticals industry, with previous leadership roles at GE Healthcare and a doctorate in biochemistry from Oxford University.
The company's primary focus is on prostate cancer, with a pipeline of precision-targeted therapeutic radiopharmaceuticals. It holds exclusive worldwide rights for the therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology, which originated at the Technical University of Munich. This technology allows for the creation of theranostic compounds that can be labeled with either diagnostic or therapeutic radioisotopes for personalized medicine. The lead programs involve labeling the rhPSMA molecule with lutetium-177 (a beta emitter) and actinium-225 (an alpha emitter), aiming to deliver high radiation doses to tumors while minimizing exposure to healthy tissues.
Blue Earth Therapeutics operates on a model of advancing its proprietary drug candidates through clinical trials to gain regulatory approval. In October 2024, the company secured $76.5 million in a Series A financing round led by Soleus Capital and Sands Capital, with participation from initial investor Bracco Imaging and others. This funding supports the progression of its lead candidates, 177Lu-rhPSMA-10.1 and 225Ac-rhPSMA-10.1, into Phase 2 clinical studies. The company is actively conducting clinical trials in the US and EU and has partnered with institutions like University College London to accelerate its research.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 47.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Precision Medicine, Biotech and Pharma, uk is8 life sciences, Radiotherapy, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2024 | $77M | $306M | Bracco · Soleus Capital · Sands Capital Management | ↗ |
| CORPORATE SPINOUTOther financing | Mar 2022 | $0 | — | Bracco | ↗ |
Growth signals
Latest recorded traffic for Blue Earth Therapeutics is 30 monthly website visits, down 98.2% over the last three months. Blue Earth Therapeutics's team grew 4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Blue Earth Therapeutics in the Oxford ecosystem
The Blue Earth Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- SCSoleus Capital
Sands Capital Management
Series B and later1 investor entered at this stage
Bracco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Blue Earth Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Blue Earth Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









